Abstract |
A joint venture between YM BioSciences (formerly York Medical) and The Center of Molecular Immunology is collaborating with Oncoscience in Europe for the development of a humanized monoclonal antibody, nimotuzumab, for the potential treatment ( TheraCIM and RadioTheraCIM) and diagnosis ( DiaCIM) of cancers of epithelial origin, such as breast, lung, head and neck, and pancreatic cancer. The antibody is currently undergoing phase II clinical trials.
|
Authors | James Spicer |
Journal | Current opinion in molecular therapeutics
(Curr Opin Mol Ther)
Vol. 7
Issue 2
Pg. 182-91
(Apr 2005)
ISSN: 1464-8431 [Print] England |
PMID | 15844627
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Radioisotopes
- nimotuzumab
- Rhenium
|
Topics |
- Animals
- Antibodies, Monoclonal
(pharmacokinetics, pharmacology, toxicity)
- Antibodies, Monoclonal, Humanized
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- Humans
- Mice
- Neoplasms
(drug therapy)
- Radioisotopes
- Rats
- Rhenium
|